Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Büller, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Di Minno, 2015, Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials, Ann Med, 47, 61, 10.3109/07853890.2014.982064 Guler, 2015, A review of the fixed dose use of new oral anticoagulants in obese patients: is it really enough?, Anatol J Cardiol, 15, 1020, 10.5152/AnatolJCardiol.2015.6532 Burnett, 2016, Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment, J Thromb Thrombolysis, 41, 206, 10.1007/s11239-015-1310-7 Frost, 2015, Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban, Clin Pharmacokinet, 54, 651, 10.1007/s40262-014-0228-0 Upreti, 2013, Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects, Br J Clin Pharmacol, 76, 908, 10.1111/bcp.12114 Kubitza, 2007, Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects, J Clin Pharmacol, 47, 218, 10.1177/0091270006296058 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Tittl, 2018, Impact of BMI on clinical outcomes of NOAC therapy in daily care—results of the prospective Dresden NOAC Registry (NCT01588119), Int J Cardiol, 262, 85, 10.1016/j.ijcard.2018.03.060 Kido, 2019, Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation, Ann Pharmacother, 53, 165, 10.1177/1060028018796604 Martin, 2016, Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH, J Thromb Haemost, 14, 1308, 10.1111/jth.13323 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Kaatz, 2015, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH, Journal Thromb Haemost, 13, 2119, 10.1111/jth.13140 Borch, 2010, Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study, Arterioscler Thromb Vasc Biol, 30, 121, 10.1161/ATVBAHA.109.188920 Ay, 2007, Venous thromboembolism—a manifestation of the metabolic syndrome, Haematologica, 92, 374, 10.3324/haematol.10828 Jang, 2009, Metabolic syndrome is associated with venous thromboembolism in the Korean population, Arterioscler Thromb Vasc Biol, 29, 311, 10.1161/ATVBAHA.109.184085 Di Minno, 2011, Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism, Thromb Res, 127, 193, 10.1016/j.thromres.2010.12.005 Steffen, 2009, Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology, J Thromb Haemost, 7, 746, 10.1111/j.1538-7836.2009.03295.x Eichinger, 2008, Overweight, obesity, and the risk of recurrent venous thromboembolism, Arch Intern Med, 168, 1678, 10.1001/archinte.168.15.1678 Cushman, 2016, Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: the longitudinal investigation of thromboembolism etiology, Thromb Res, 144, 127, 10.1016/j.thromres.2016.06.012 Hunt, 2018, Hemostasis at extremes of body weight, Semin Thromb Hemost, 44, 632, 10.1055/s-0038-1661385 Domienik-Karlowicz, 2016, The use of anticoagulants in morbidly obese patients, Cardiol J, 23, 12, 10.5603/CJ.a2015.0054 Graves, 2017, Use of oral anticoagulants in obese patients, JSM Atheroscler, 2, 1035